Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Indolent Systemic Mastocytosis
NCT03770273Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2019
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in indolent systemic mastocytosis (ISM) comparing Sarilumab Arm with Placebo Arm (2 arms). Primary endpoints: Mastocytosis Quality of Life Questionnaire at 16 weeks and Number of Participants With Adverse Events by Grade at 32 weeks. Started Jun 2019; status: completed.
02
Drugs
sarilumab
03
Conditions
indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on NCT03770273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770273.